| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 09/22/2023 | 265.85% | Needham | → $3 | Reiterates | Buy → Buy |
| 09/22/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 09/08/2023 | 265.85% | Needham | → $3 | Reiterates | Buy → Buy |
| 09/07/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 08/07/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 08/04/2023 | 265.85% | Needham | → $3 | Reiterates | Buy → Buy |
| 08/01/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 08/01/2023 | 509.76% | Cantor Fitzgerald | → $5 | Reiterates | Overweight → Overweight |
| 06/26/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 05/15/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 05/12/2023 | 265.85% | Needham | → $3 | Reiterates | Buy → Buy |
| 04/18/2023 | 265.85% | Needham | → $3 | Reiterates | → Buy |
| 03/24/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 03/23/2023 | 631.71% | HC Wainwright & Co. | $6.5 → $6 | Maintains | Buy |
| 03/08/2023 | 509.76% | Cantor Fitzgerald | → $5 | Reiterates | → Overweight |
| 03/01/2023 | 692.68% | HC Wainwright & Co. | → $6.5 | Reiterates | → Buy |
| 01/25/2023 | 692.68% | HC Wainwright & Co. | $6 → $6.5 | Maintains | Buy |
| 05/12/2022 | 631.71% | HC Wainwright & Co. | $7.5 → $6 | Maintains | Buy |
| 09/22/2021 | 875.61% | Aegis Capital | $9 → $8 | Maintains | Buy |
| 09/22/2021 | — | WBB Securities | Upgrades | Buy → Strong Buy | |
| 03/04/2021 | 997.56% | Aegis Capital | → $9 | Initiates Coverage On | → Buy |
| 08/26/2020 | 509.76% | Citigroup | $6 → $5 | Maintains | Buy |
| 03/05/2020 | 631.71% | Needham | $10 → $6 | Maintains | Buy |
| 12/04/2019 | 662.2% | WBB Securities | → $6.25 | Upgrades | Speculative Buy → Buy |
| 09/04/2019 | — | Wedbush | Upgrades | Neutral → Outperform | |
| 06/06/2019 | 631.71% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
| 05/17/2019 | 143.9% | Wedbush | $7 → $2 | Downgrades | Outperform → Neutral |
| 03/01/2019 | 753.66% | Wedbush | $12 → $7 | Maintains | Outperform |
What is the target price for Cidara Therapeutics (CDTX)?
The latest price target for Cidara Therapeutics (NASDAQ: CDTX) was reported by HC Wainwright & Co. on November 6, 2023. The analyst firm set a price target for $6.00 expecting CDTX to rise to within 12 months (a possible 631.71% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cidara Therapeutics (CDTX)?
The latest analyst rating for Cidara Therapeutics (NASDAQ: CDTX) was provided by HC Wainwright & Co., and Cidara Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Cidara Therapeutics (CDTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cidara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cidara Therapeutics was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
Is the Analyst Rating Cidara Therapeutics (CDTX) correct?
While ratings are subjective and will change, the latest Cidara Therapeutics (CDTX) rating was a reiterated with a price target of $0.00 to $6.00. The current price Cidara Therapeutics (CDTX) is trading at is $0.82, which is within the analyst's predicted range.